Tetrahydroberberrubine attenuates lipopolysaccharide-induced acute lung injury by down-regulating MAPK, AKT, and NF-κB signaling pathways
- PMID: 27470389
- DOI: 10.1016/j.biopha.2016.05.025
Tetrahydroberberrubine attenuates lipopolysaccharide-induced acute lung injury by down-regulating MAPK, AKT, and NF-κB signaling pathways
Abstract
Acute lung injury (ALI) is a life-threatening syndrome that is characterized by overwhelming lung inflammation and increased microvascular permeability, which causes a high mortality worldwide. Here, we studied the protective effect of tetrahydroberberrubine (THBru), a berberine derivative, on a mouse model of lipopolysaccharide (LPS)-induced acute lung injury that was established in our previous studies. The results showed that a single oral administration of THBru significantly decreased the lung wet to dry weight (W/D) ratio at doses of 2, 10 and 50mg/kg administered 1h prior to LPS challenge (30mg/kg, intravenous injection). Histopathological changes, such as pulmonary edema, infiltration of inflammatory cells and coagulation, were also attenuated by THBru. In addition, THBru markedly decreased the total cell counts, total protein and nitrate/nitrite content in bronchoalveolar lavage fluid (BALF), significantly decreased tumor necrosis factor-α (TNF-α) and nitrate/nitrite content in the plasma, and reduced the myeloperoxidase (MPO) activity in the lung tissues. Additionally, THBru (10μM) significantly decreased the content of TNF-α and nitric oxide (NO) in LPS-induced THP-1 cells in vitro. Moreover, THBru significantly suppressed the activation of the MAPKs JNK and p38, AKT, and the NF-κB subunit p65 in LPS-induced THP-1 cells. These findings confirm that THBru attenuates LPS-induced acute lung injury by inhibiting the release of inflammatory cytokines and suppressing the activation of MAPKs, AKT, and NF-κB signaling pathways, which implicates it as a potential therapeutic agent for ALI or sepsis.
Keywords: Acute lung injury; Berberine; Lipopolysaccharide; Signaling pathways; THP-1 cells; Tetrahydroberberrubine.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-κB.Int Immunopharmacol. 2012 Jan;12(1):88-93. doi: 10.1016/j.intimp.2011.10.018. Epub 2011 Nov 8. Int Immunopharmacol. 2012. PMID: 22079591
-
Total flavonoids of Mosla scabra leaves attenuates lipopolysaccharide-induced acute lung injury via down-regulation of inflammatory signaling in mice.J Ethnopharmacol. 2013 Jul 30;148(3):835-41. doi: 10.1016/j.jep.2013.05.020. Epub 2013 Jun 6. J Ethnopharmacol. 2013. PMID: 23747643
-
Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway.Int Immunopharmacol. 2011 Oct;11(10):1606-12. doi: 10.1016/j.intimp.2011.05.022. Epub 2011 Jun 1. Int Immunopharmacol. 2011. PMID: 21640201
-
Protective effect of berberine against LPS-induced injury in the intestine: a review.Cell Cycle. 2022 Nov;21(22):2365-2378. doi: 10.1080/15384101.2022.2100682. Epub 2022 Jul 19. Cell Cycle. 2022. PMID: 35852392 Free PMC article. Review.
-
Ameliorating effects of berberine on sepsis-associated lung inflammation induced by lipopolysaccharide: molecular mechanisms and preclinical evidence.Pharmacol Rep. 2023 Aug;75(4):805-816. doi: 10.1007/s43440-023-00492-2. Epub 2023 May 15. Pharmacol Rep. 2023. PMID: 37184743 Review.
Cited by
-
Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.Pharmacol Res. 2021 Jan;163:105224. doi: 10.1016/j.phrs.2020.105224. Epub 2020 Sep 29. Pharmacol Res. 2021. PMID: 33007416 Free PMC article. Review.
-
Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?Biomed Pharmacother. 2021 Feb;134:111143. doi: 10.1016/j.biopha.2020.111143. Epub 2020 Dec 16. Biomed Pharmacother. 2021. PMID: 33360048 Free PMC article. Review.
-
Emodin Protects Against Lipopolysaccharide-Induced Acute Lung Injury via the JNK/Nur77/c-Jun Signaling Pathway.Front Pharmacol. 2022 Mar 17;13:717271. doi: 10.3389/fphar.2022.717271. eCollection 2022. Front Pharmacol. 2022. PMID: 35370650 Free PMC article.
-
THBru attenuates diabetic cardiomyopathy by inhibiting RAGE-dependent inflammation.Acta Pharmacol Sin. 2024 Oct;45(10):2107-2118. doi: 10.1038/s41401-024-01307-7. Epub 2024 Jun 11. Acta Pharmacol Sin. 2024. PMID: 38862818
-
Renin-angiotensin system inhibitors mitigate radiation pneumonitis by activating ACE2-angiotensin-(1-7) axis via NF-κB/MAPK pathway.Sci Rep. 2023 May 23;13(1):8324. doi: 10.1038/s41598-023-35412-0. Sci Rep. 2023. PMID: 37221286 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous